Study of serplulimab plus chemotherapy before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (serplulimab) and two chemotherapy drugs (nab-paclitaxel and cisplatin) given before surgery for esophageal cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improve outcomes for patients with stage IB to III esophageal squamous cell carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a type of esophageal cancer called squamous cell carcinoma that can be surgically removed.
- Your cancer must be at stage IB to III based on specific tumor and lymph node measurements.
- You must have not had any prior cancer treatment like chemotherapy, radiation, or surgery for this cancer.
- Your major organs (blood, liver, kidneys, lungs) must be working well enough, which will be checked with tests.
- You must be able to eat liquid food and handle surgery safely.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before surgery can improve outcomes for people with locally advanced, operable esophageal squamous cell carcinoma. It may help shrink the tumor and improve the chance of successful surgery.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.